Abstract
Background:
The objective of the study was to assess the effect of atorvastatin on inflammation markers and low-density lipoprotein (LDL) subfractions.
Methods:
In a prospective, randomized, double-blind pilot study involving 28 adolescents with type 1 diabetes (T1D), lipoprotein-associated phospholipase A2 (Lp-PLA2) activity, high-sensitivity C-reactive protein (hsCRP), and subfractions of LDL were measured at baseline, after 1 year and 2 years of treatment with atorvastatin (10 mg/day) vs. placebo.
Results:
For the atorvastatin group, we found posttreatment reductions of Lp-PLA2 activity (p<0.001), LDL cholesterol (p=0.001), non-small dense LDL cholesterol (p<0.001), total cholesterol (p<0.001), and apolipoprotein B (apo B) (p<0.001), whereas small dense LDL cholesterol and hsCRP did not change significantly.
Conclusions:
In adolescents with T1D, long-term treatment with atorvastatin is safe and may reduce cardiovascular risk by significant decreases of Lp-PLA2 activity and LDL cholesterol.
Conflict of interest statement: Neither the authors nor the funders have any conflict of interest associated with this manuscript.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: The study was supported by grants of Pfizer GmbH, Germany. Karl Otfried Schwab is a member of the PATRO Children study board at Sandoz Biopharmaceuticals. He received research grants by Ipsen Pharma, Pfizer, Sandoz, Serono-Merck, Synageva, and Vitaflo.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Kiess W, Gorski T, Penke M, Klamt S, Kapellen TM. Diabetes mellitus in children and adolescents – a global epidemic which has become neglected. J Pediatr Endocrinol Metab 2015;28:247–50.10.1515/jpem-2015-0900Search in Google Scholar
2. Urbina EM, Dabelea D, D’Agostino Jr RB, Shah AS, Dolan LM, et al. Effect of type 1 diabetes on carotid structure and function in adolescents and young adults. Diabetes Care 2013;36:2597–99.10.2337/dc12-2024Search in Google Scholar
3. Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: From pathophysiology to practice. J Am Coll Cardiol 2009;54:2129–38.10.1016/j.jacc.2009.09.009Search in Google Scholar
4. Snell-Bergeon JK, West NA, Mayer-Davis EJ, Liese AD, Marcovina SM, et al. Inflammatory markers are increased in youth with type 1 diabetes: The SEARCH case-control study. J Clin Endocrinol Metab 2010;95:2868–76.10.1210/jc.2009-1993Search in Google Scholar
5. Rosenson RS, Stafforini DM. Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2. J Lipid Res 2012;53:1767–82.10.1194/jlr.R024190Search in Google Scholar
6. Lavi S, McConnell JP, Rihal CS, Prasad A, Mathew V, et al. Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation. Association with early coronary atherosclerosis and endothelial dysfunction in humans. Circulation 2007;115:2715–21.10.1161/CIRCULATIONAHA.106.671420Search in Google Scholar
7. McIntyre TM, Prescott SM, Stafforini DM. The emerging roles of PAF acetylhydrolase. J Lipid Res 2009;50:S255–9.10.1194/jlr.R800024-JLR200Search in Google Scholar
8. Lp-PLA(2) Studies Collaboration, Thompson A, Gao P, Orfei L, Watson S, et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010;375:1536–44.10.1016/S0140-6736(10)60319-4Search in Google Scholar
9. Winkler K, Hoffmann MM, Winkelmann BR, Friedrich I, Schäfer G, et al. Lipoprotein-associated phospholipase A2 predicts 5-year cardiac mortality independently of established risk factors and adds prognostic information in patients with low and medium high-sensitivity C-reactive protein (the Ludwigshafen risk and cardiovascular health study). Clin Chem 2007;53:1440–7.10.1373/clinchem.2007.086298Search in Google Scholar PubMed
10. Hatoum IJ, Hu FB, Nelson JJ, Rimm EB. Lipoprotein-associated phospholipase A2 activity and incident coronary heart disease among men and women with type 2 diabetes. Diabetes 2010;59:1239–43.10.2337/db09-0730Search in Google Scholar PubMed PubMed Central
11. Winkler K, Hoffmann MM, Krane V, Drechsler C, Wanner C. Lipoprotein-associated phospholipase A2 and outcome in patients with type 2 diabetes on haemodialysis. Eur J Clin Invest 2012;42:693–701.10.1111/j.1365-2362.2011.02634.xSearch in Google Scholar PubMed
12. Livingstone SJ, Looker HC, Hothersall EJ, Wild SH, Lindsay RS, et al. Risk of cardiovascular disease and total mortality in adults with type 1 diabetes: Scottish registry linkage study. PLoS Med 2012;9:e1001321.10.1371/journal.pmed.1001321Search in Google Scholar PubMed PubMed Central
13. Miller RG, Costacou T, Orchard TJ. Lipoprotein-associated phospholipase A2, C-reactive protein, and coronary artery disease in individuals with type 1 diabetes and macroalbuminuria. Diab Vasc Dis Res 2010;7:47–55.10.1177/1479164109346358Search in Google Scholar PubMed PubMed Central
14. Kinney GL, Snell-Bergeon JK, Maahs DM, Eckel RH, Ehrlich J, et al. Lipoprotein-associated phospholipase A2 activity predicts progression of subclinical atherosclerosis. Diabetes Technol Ther 2011;13:381–87.10.1089/dia.2010.0175Search in Google Scholar PubMed PubMed Central
15. Saougos VG, Tambaki AP, Kalogirou M, Kostapanos M, Gazi IF, et al. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2. Arterioscler Thromb Vasc Biol 2007;27:2236–43.10.1161/ATVBAHA.107.147280Search in Google Scholar PubMed
16. Schaefer EJ, McNamara JR, Asztalos BF. Taylor T, Daly JA, et al. Effects of atorvastatin versus other statins on fasting and postprandial C- reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects. Am J Cardiol 2005;95:1025–32.10.1016/j.amjcard.2005.01.023Search in Google Scholar PubMed
17. Steen DL, O’Donoghue ML. Lp-PLA2 inhibitors for the reduction of cardiovascular events. Cardio Ther 2013;2:125–34.10.1007/s40119-013-0022-3Search in Google Scholar PubMed PubMed Central
18. Silverstein J, Klingensmith G, Copeland K, Plotnick L, Kaufman F, et al. Care of children and adolescents with type 1 diabetes. Diabetes Care 2005;28:186–212.10.2337/diacare.28.1.186Search in Google Scholar PubMed
19. Krebs A, Schmidt-Trucksäss A, Doerfer J, Grulich-Henn J, Holder M, et al. Cardiovascular risk in pediatric type 1 diabetes: sex-specific intima-media thickening verified by automatic contour identification and analyzing systems. Pediatr Diabetes 2012;13:251–8.10.1111/j.1399-5448.2011.00814.xSearch in Google Scholar PubMed
20. Schaffrath Rosario A, Kurth B-M, Stolzenberg H, Ellert U, Neuhauser H. Body mass index percentiles for children and adolescents in Germany based on a nationally representative sample (KiGGS 2003–2006). Eur J Clin Nutr 2010;64:341–9.10.1038/ejcn.2010.8Search in Google Scholar PubMed
21. Winkler K, Abletshauser C, Hoffmann MM, Friedrich I, Baumstark MW, et al. Effect of fluvastatin slow-release on low-density lipoprotein (LDL) subfractions in patients with type 2 diabetes mellitus: baseline LDL profile determines specific mode of action. J Clin Endocrinol Metab 2002;87:5485–90.10.1210/jc.2002-020370Search in Google Scholar
22. Kosaka T, Yamaguchi M, Soda Y, Kishimoto T, Tago A, et al. Spectrophotometric assay for serum platelet-activating factor acetylhydrolase activity. Clin Chim Acta 2000;296:151–61.10.1016/S0009-8981(00)00216-3Search in Google Scholar
23. McCrindle BW, Urbina EM, Dennison BA, Jacobson MS, Steinberger J, et al. Drug therapy of high-risk lipid abnormalities in children and adolescents. A Scientific Statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council on Cardiovascular Nursing. Circulation 2007;115:1948–67.10.1161/CIRCULATIONAHA.107.181946Search in Google Scholar PubMed
24. Newman C, Tsai J, Szarek M, Luo D, Gibson E. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Am J Cardiol 2006;97:61–7.10.1016/j.amjcard.2005.07.108Search in Google Scholar PubMed
25. da Silva IT, Timm Ade S, Damasceno NR. Influence of obesity and cardiometabolic makers on lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in adolescents: the healthy young cross-sectional study. Lipids Health Dis 2013;12:19.10.1186/1476-511X-12-19Search in Google Scholar PubMed PubMed Central
26. Nagel G, Rapp K, Wabitsch M, Büchele G, Kroke A, et al. Prevalence and cluster of cardiometabolic biomarkers in overweight and obese schoolchildren: results from a large survey in southwest Germany. Clin Chem 2008;54:317–25.10.1373/clinchem.2007.094821Search in Google Scholar PubMed
27. Verona J, Gilligan LE, Gimenez C, Verona MF, Lombardo SM, et al. Physical activity and cardiometabolic risk in male children and adolescents: the Balcarce study. Life Sci 2013;93:64–8.10.1016/j.lfs.2013.05.021Search in Google Scholar PubMed
28. Ryu SK, Hutten BA, Vissers MN, Wiegman A, Kastelein JJ, et al. Lipoprotein-associated phospholipase A2 mass and activity in children with heterozygous familial hypercholesterolemia and unaffected siblings: Effect of pravastatin. J Clin Lipidol 2011;5:50–6.10.1016/j.jacl.2010.11.001Search in Google Scholar PubMed
29. Gomes MB, Cobas RA, Nunes E, Nery M, Castro-Faria-Neto HC, et al. Serum platelet-activating factor acetylhydrolase activity: a novel potential inflammatory a marker in type 1 diabetes. Prostaglandins Other Lipid Mediat 2008;87:42–6.10.1016/j.prostaglandins.2008.07.001Search in Google Scholar PubMed
30. de Castro SH, Castrol-Faria-Neto HC, Gomes MB. Platelet-activating factor acetylhydrolase (PAF-AH) activity in patients with type 1 diabetes mellitus. Arq Bras Cardiol 2007;88:156–61.Search in Google Scholar
31. Ridker PM, MacFadyen JG, Wolfert RL, Koenig W. Relationship of lipoprotein-associated phospholipase A2 mass and activity with incident vascular events among primary prevention patients allocated to placebo or statin therapy: an analyses from the JUPITER trial. Clin Chem 2012;58:877–86.10.1373/clinchem.2011.180281Search in Google Scholar PubMed
32. Canas JA, Ross JL, Taboada MV, Sikes KM, Damaso LC, et al. A randomized, double blind, placebo-controlled pilot trial of the safety and efficacy of atorvastatin in children with elevated low-density lipoprotein cholesterol (LDL-C) and type 1 diabetes. Pediatr Diabetes 2015;16:79–89.10.1111/pedi.12245Search in Google Scholar PubMed
33. Nozue T, Michishita I, Ito Y, Hirano T. Effects of statin on small dense low-density lipoprotein cholesterol and remnant-like particle cholesterol in heterozygous familial hypercholesterolemia. J Atheroscler Thromb 2008;15:146–53.10.5551/jat.E552Search in Google Scholar PubMed
34. Krebs A, Kratzin T, Doerfer J, Winkler K, Wurm M, et al. Decrease of small dense LDL and lipoprotein-associated phospholipase A2 due to human growth hormone treatment in short children with growth hormone deficiency and small for gestational age status. J Pediatr Endocrinol Metab 2016;29:203–8.10.1515/jpem-2015-0148Search in Google Scholar PubMed
35. Schwab KO, Doerfer J, Scheidt-Nave C, Kurth BM, Hungele A, et al. Algorithm-based cholesterol monitoring in children with type 1 diabetes. J Pediatr 2014;164:1079–84.10.1016/j.jpeds.2013.12.038Search in Google Scholar PubMed
36. Gallo LM, Silverstein JH, Shuster JJ, Haller MJ. Arterial stiffness, lipoprotein particle size, and lipoprotein particle concentration in children with type 1 diabetes. J Pediatr Endocrinol Metab 2010;23:661–67.10.1515/JPEM.2010.23.7.661Search in Google Scholar
©2016 Walter de Gruyter GmbH, Berlin/Boston
